The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
DICERNA PHARMACEUTICALS INC | COM | 253031108 | 62,098 | 3,080,237 | SH | SOLE | 3,080,237 | 0 | 0 | ||
MARINUS PHARMACEUTICALS INC | COM NEW | 56854Q200 | 16,285 | 1,431,058 | SH | SOLE | 1,431,058 | 0 | 0 | ||
SOLID BIOSCIENCES INC | COM | 83422E105 | 18,953 | 7,929,918 | SH | SOLE | 7,929,918 | 0 | 0 | ||
APTINYX INC | COM | 03836N103 | 20,807 | 8,891,758 | SH | SOLE | 8,891,758 | 0 | 0 | ||
SPRINGWORKS THERAPEUTICS INC | COM | 85205L107 | 306,498 | 4,831,307 | SH | SOLE | 4,831,307 | 0 | 0 | ||
DYNAVAX TECHNOLOGIES CORP | COM NEW | 268158201 | 161,652 | 8,415,000 | SH | SOLE | 8,415,000 | 0 | 0 | ||
X4 PHARMACEUTICALS INC | COM | 98420X103 | 11,212 | 2,119,540 | SH | SOLE | 2,119,540 | 0 | 0 | ||
SAVARA INC | COM | 805111101 | 16,039 | 11,622,598 | SH | SOLE | 11,622,598 | 0 | 0 | ||
ARCUTIS BIOTHERAPEUTICS INC. | COM | 03969K108 | 95,065 | 3,979,292 | SH | SOLE | 3,979,292 | 0 | 0 | ||
MERSANA THERAPEUTICS INC. | COM | 59045L106 | 34,850 | 3,695,667 | SH | SOLE | 3,695,667 | 0 | 0 | ||
CRINETICS PHARMACEUTICALS | COM | 22663K107 | 35,358 | 1,679,701 | SH | SOLE | 1,679,701 | 0 | 0 | ||
AEGLEA BIO THERAPEUTICS INC | COM | 00773J103 | 22,639 | 2,847,689 | SH | SOLE | 2,847,689 | 0 | 0 | ||
ANNEXON INC | COM | 03589W102 | 60,327 | 3,241,628 | SH | SOLE | 3,241,628 | 0 | 0 | ||
NURIX THERAPEUTICS INC | COM | 67080M103 | 38,478 | 1,284,314 | SH | SOLE | 1,284,314 | 0 | 0 | ||
RAPID MICRO BIOSYSTEMS INC | CLASS A COM | 75340L104 | 155,786 | 8,434,560 | SH | SOLE | 8,434,560 | 0 | 0 | ||
RESEARCH ALLIANCE CORP II | COM CL A | 760873109 | 9,850 | 1,000,000 | SH | SOLE | 1,000,000 | 0 | 0 | ||
NAUTILUS BIOTECHNOLOGY INC | COM | 63909J108 | 12,280 | 2,000,000 | SH | SOLE | 2,000,000 | 0 | 0 | ||
TANGO THERAPEUTICS INC | COM | 87583X109 | 24,849 | 1,921,790 | SH | SOLE | 1,921,790 | 0 | 0 | ||
SYROS PHARMACEUTICALS INC | COM | 87184Q107 | 25,859 | 5,785,036 | SH | SOLE | 5,785,036 | 0 | 0 | ||
ATEA PHARMACEUTICALS INC | COM | 04683R106 | 129,722 | 3,700,000 | SH | SOLE | 3,700,000 | 0 | 0 | ||
C4 THERAPEUTICS INC | COM STK | 12529R107 | 73,374 | 1,642,209 | SH | SOLE | 1,642,209 | 0 | 0 | ||
BCLS ACQUISITION CORP | COM CL A | G0904B105 | 4,856 | 487,500 | SH | SOLE | 487,500 | 0 | 0 | ||
JIYA ACQUISITION CORP | COM CL A | 47760M102 | 2,925 | 300,000 | SH | SOLE | 300,000 | 0 | 0 | ||
HELIX ACQUISITION CORP | COM CL A | G4444C102 | 2,488 | 250,000 | SH | SOLE | 250,000 | 0 | 0 | ||
FRAZIER LIFESCIENCES ACQU CO | UNIT 12/09/2025 | G3710A121 | 3,009 | 300,000 | SH | SOLE | 300,000 | 0 | 0 | ||
PHARVARIS N V | COM | N69605108 | 56,392 | 3,180,601 | SH | SOLE | 3,180,601 | 0 | 0 | ||
ARYA SCIENCES ACQU CORP IV | CL A | G31659108 | 7,035 | 700,000 | SH | SOLE | 700,000 | 0 | 0 | ||
PANACEA ACQUISITION CORP II | CL A SHS | G6882C106 | 4,885 | 500,000 | SH | SOLE | 500,000 | 0 | 0 | ||
BLUEBIRD BIO INC | COM | 09609G100 | 7,239 | 538,179 | SH | SOLE | 538,179 | 0 | 0 | ||
OMEGA ALPHA SPAC | CL A | G6749V107 | 3,894 | 400,000 | SH | SOLE | 400,000 | 0 | 0 | ||
NUVALENT INC | COM | 670703107 | 77,302 | 3,428,014 | SH | SOLE | 3,428,014 | 0 | 0 | ||
ADAGIO THERAPEUTICS INC | COM | 00534A102 | 105,060 | 2,487,207 | SH | SOLE | 2,487,207 | 0 | 0 | ||
ARYA SCIENCES ACQUISITN CORP | CLASS A ORD SHS | G31658100 | 4,940 | 500,000 | SH | SOLE | 500,000 | 0 | 0 |